Cryptococcal meningitis: a review of cryptococcal antigen screening programs in Africa

Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa

OBJECTIVES Cryptococcal meningitis (CM)-related mortality may be prevented by screening patients for sub-clinical cryptococcal antigenaemia (CRAG) at antiretroviral-therapy (ART) initiation and pre-emptively treating those testing positive. Prior to programmatic implementation in South Africa we performed a cost-effectiveness analysis of alternative preventive strategies for CM. DESIGN Cost-e...

Cryptococcal Meningitis

Virulence probably plays a relatively small role in the outcome of this infection: the crucial factor is the immune status of the host. The most serious infections usually develop, in fact, in patients with defective cell-mediated immunity, for example those with AIDS, organ transplantation, reticuloendothelial malignancy, corticosteroid treatment and sarcoidosis, but not in subjects with neutr...

Cryptococcal meningitis

© 2004 Blackwell Publishing Ltd the second most common cause of death in HIV infection after tuberculosis (French et al. 2002). Moreover, despite the availability of highly active antiretroviral therapy (HAART), it continues to pose diffi cult management questions in the industrialized world. Questions remain for physicians regarding the optimal combination of antifungal agents, duration of tre...

Cryptococcal antigen test revisited: significance for cryptococcal meningitis therapy monitoring in a tertiary chinese hospital.

For a total of 29 non-human immunodeficiency virus 1 cryptococcal meningitis cases, titer changes in the latex agglutination test before and after therapy were reviewed along with clinical manifestations, laboratory findings, and therapy regimens. The cryptococcal antigen titer decreased for every case after therapy and was correlated to fungal clearance as defined by fungus smear and/or cultur...

Cryptococcal Meningitis in a Horse